Ananda Developments PLC Research Roundup
05 January 2023 - 6:15PM
RNS Non-Regulatory
TIDMANA
Ananda Developments PLC
05 January 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda is an AQSE-listed medical cannabis company creating
UK-based operations to grow and provide carbon zero, consistent,
medical cannabis for the UK and international markets.
Medical Cannabis Research Roundup
Issue Fifteen
Summary:
Happy New Year! The last couple of months of 2022 produced
several significant papers on the evidence for medical cannabis.
The list included a number of papers on cannabis and its
constituents (i.e. cannabinoids, terpenes, flavonoids etc) and the
mechanisms by which they act illustrating the greater understanding
that is being generated in the scientific community with regard to
medical cannabis and its mechanisms of action. However, below, we
cover a few interesting papers that deal with patient experience
with medical cannabis. You will note that while there is a lot of
potential shown the call is for more trials with more consistent
forms of medical cannabis.
-- Study finds medical cannabis is beneficial in women with treatment resistant Fibromyalgia .
-- One of the first studies in Japan on intractable epilepsy and CBD shows effectiveness of CBD for reducing
seizures .
-- Study using Low Doses of CBD plus anti-convulsant shows efficacy.
-- A US survey of medical cannabis use during perimenopause and post-menopause shows beneficial effects .
STUDY FINDS MEDICAL CANNABIS IS BENEFICIAL IN WOMEN WITH
TREATMENT RESISTANT FIBROMYALGIA
-- Fibromyalgia is a pain-focused syndrome involving diffuse chronic muscle pain, sleep disturbances, and cognitive
and functional impairments.
-- Fibromyalgia affects approximately 3% of the general population. Women are affected two times more than men.
-- 30 women diagnosed with fibromyalgia and having exhausted pharmacological treatment were assessed for Quality of
Life scores, out of 5, prior to medical cannabis treatment and again after one month.
-- The General quality of life scores went from an average of 1.47/5.00 to 3.43/5.00, a significant improvement!
-- Given the small number of participants and the short-term treatment further longer term wider cohort studies are
recommended.
ONE OF THE FIRST STUDIES IN JAPAN ON INTRACTABLE EPILEPSY AND
CBD SHOWS EFFECTIVENESS OF CBD FOR REDUCING SEIZURES
-- Despite very strict cannabis regulations in Japan, some cannabidiol (CBD) products have been legally distributed
since 2013 and taken by some patients with epilepsy.
-- A self-administered questionnaire was sent to 38 patients with intractable epilepsy who were taking CBD
-- The median CBD intake was 12.0 mg/kg/day NB: Product was CBD isolate.
-- Fifteen patients (53.6%) reported a decrease in seizure frequency. Moreover, two patients (7.1%) showed complete
resolution of seizures.
-- No significant correlation was found between the patient's diagnosis and seizure type or treatment efficacy.
-- Conclusions: This is the first cross-sectional study of CBD users in Japan suggesting that CBD may be an
effective option for Asian patients with refractory epilepsy, regardless of diagnosis or seizure type.
STUDY USING LOW DOSES OF CBD PLUS ANTI-CONVULSANT SHOWS
EFFICACY
-- Thirty-four patients were included in the study over 12 months.
-- A high proportion of patients, 16, concluded the study with a total control of the seizures reaching a 100%
improvement, 12 reported >= 75% improvement, 3 >= 50%, and 2 >= 25%; only 1 patient had an improvement of less
than 25%.
-- This is the first Latin American study that demonstrates that long-term CBD added to the usual drugs
significantly reduces the frequency, duration, and type of seizures in the different aetiologies of epilepsy,
being especially effective on the seizures that are the most incapacitating, improving the quality of life of the
individual and their family.
-- The CBD used by the population in our study was sublingual PhytoCBD Oil at two different doses: (i) 3% CBD oil
with 0.02% THC and (ii) 15% CBD oil with 0.02% THC, administered twice a day with an average dose of 1 mg/kg/day,
ranging from 0.32 to 2.4 mg/kg/day.
A US SURVEY OF MEDICAL CANNABIS USE DURING PERIMENOPAUSE AND
POST-MENOPAUSE SHOWS BENEFICIAL EFFECTS.
-- Most participants reported current cannabis use (86.1%) and endorsed using medical cannabis for menopause-related
symptoms (78.7%).
-- The top menopause-related symptoms for medical cannabis use were sleep disturbance (67.4%) and mood/anxiety
(46.1%).
-- Results suggest that many individuals are currently using medical cannabis as an adjunctive treatment for
menopause-related symptoms, particularly sleep disturbance and mood/anxiety.
-- Future research should examine the impact of different MC use characteristics (e.g., cannabinoid profiles) on the
efficacy of MC use for menopause-related symptoms. Increased severity and prevalence of mood and anxiety symptoms
in perimenopausal participants suggest promising targets for clinical trials of cannabinoid-based therapies.
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
Chief Executive Officer
Melissa Sturgess
Investor Relations
Jeremy Sturgess-Smith
PETERHOUSE CAPITAL LIMITED +44 (0)20 7469 0930
Corporate Finance
Mark Anwyl
Corporate Broking
Lucy Williams
Duncan Vasey
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company creating
UK-based operations to grow and provide carbon zero, consistent,
medical cannabis for the UK and international markets.
For more information, please visit:
https://anandadevelopments.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABUGDBDDGDGXS
(END) Dow Jones Newswires
January 05, 2023 02:15 ET (07:15 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Apr 2024 to May 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From May 2023 to May 2024